Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery ...Middle East

PR Newswire - News
TAIPEI, Nov. 4, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TW) reports completion and successful top-line results from CPN-303, a Phase 3 clinical study of APP13007 (GPN00833), conducted in Chinese cataract surgery patients by licensee, Grand Pharma (0512.HK). APP13007, a...

Read More Details
Finally We wish PressBee provided you with enough information of ( Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery )

Also on site :